<p>AbCellera Biologics Inc.（纳斯达克代码：ABCL - 获取免费报告）周四的盘中交易中股价上涨了 6.7%。该公司的股价最高达到 3.62 美元，最后交易价格为 3.5750 美元。交易期间大约有 550,779 股成交，较日均成交量 4,950,974 股下降了 89%。该股此前收盘价为 3.35 美元。</p>
<p>获取 <strong>AbCellera Biologics</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>Argenx 股价上涨 28% 及其有前景的产品提升了投资者信心</li>
</ul>
<p>ABCL 近期成为多份分析师报告的主题。Leerink Partners 在 11 月 7 日的研究报告中将 AbCellera Biologics 的评级从 “强力买入” 下调至 “持有”。Leerink Partners 在 11 月 7 日的研究报告中重新发布了 “市场表现” 评级，并对 AbCellera Biologics 的股票设定了 4.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 AbCellera Biologics 的 “卖出（d-）” 评级。最后，Wall Street Zen 在 11 月 8 日的报告中将 AbCellera Biologics 的评级从 “持有” 下调至 “卖出”。三位投资分析师给予该股 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “持有”，平均目标价为 7.75 美元。</p>
<p><strong>查看我们关于 ABCL 的最新股票报告</strong></p>
<h2>AbCellera Biologics 价格表现</h2>
<p>该公司的 50 日简单移动平均线为 4.43 美元，200 日简单移动平均线为 4.28 美元。该公司的市值为 10.7 亿美元，市盈率为-6.25，贝塔值为 0.73。</p>
<p>AbCellera Biologics（纳斯达克代码：ABCL - 获取免费报告）最近在 11 月 6 日公布了季度财报。该公司报告季度每股收益为（0.19 美元），低于分析师一致预期的（0.17 美元）2 美分。该公司季度收入为 651 万美元，而分析师预期为 633 万美元。AbCellera Biologics 的股本回报率为-17.21%，净利润率为-493.42%。整体来看，分析师预测 AbCellera Biologics Inc.今年每股收益将为-0.59 美元。</p>
<h2>对 AbCellera Biologics 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近增加或减少了对该公司的持股。Tudor Investment Corp ET AL 在第三季度购买了价值约 367.3 万美元的 AbCellera Biologics 新头寸。Advisory Services Network LLC 在第三季度购买了价值 132,000 美元的 AbCellera Biologics 新头寸。Caxton Associates LLP 在第三季度收购了价值 179.8 万美元的 AbCellera Biologics 新股份。Voleon Capital Management LP 在第三季度购买了价值 56,000 美元的 AbCellera Biologics 新股份。最后，Sherbrooke Park Advisers LLC 在第三季度收购了价值 87,000 美元的 AbCellera Biologics 新头寸。61.42% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于 AbCellera Biologics</h2>
<p>（获取免费报告）</p>
<p>AbCellera Biologics Inc.构建了一个用于抗体药物发现和开发的引擎。其引擎从自然免疫反应中发现抗体，这些抗体经过预富集。该公司的临床前产品包括用于代谢和内分泌疾病的 ABCL635，以及用于特应性皮炎的 ABCL575。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 AbCellera Biologics</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
<li>如何开始投资房地产</li>
<li>3 只便宜的股息股票可以战胜通货膨胀并支付你等待的费用</li>
<li>专家股票交易心理学技巧</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 AbCellera Biologics 吗？</h2>
<p>在你考虑 AbCellera Biologics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 AbCellera Biologics 并不在名单上。</p>
<p>虽然 AbCellera Biologics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABCL

<p>AbCellera Biologics（纳斯达克代码：ABCL）股票在午盘交易中上涨了 6.7%，达到了$3.5750。尽管上涨，分析师的评级却不一：3 个买入，3 个持有，1 个卖出。平均评级为持有，目标价为$7.75。最近的财报未能达到预期，报告每股亏损$0.19。机构投资者持有 61.42% 的股份。该公司专注于抗体药物的发现</p>

<p>AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report)'s stock price was up 6.7% during mid-day trading on Thursday . The company traded as high as $3.62 and last traded at $3.5750. Approximately 550,779 shares changed hands during trading, a decline of 89% from the average daily volume of 4,950,974 shares. The stock had previously closed at $3.35.</p>
<div class="lb-trans"><p>AbCellera Biologics Inc.（纳斯达克代码：ABCL - 获取免费报告）周四的盘中交易中股价上涨了 6.7%。该公司的股价最高达到 3.62 美元，最后交易价格为 3.5750 美元。交易期间大约有 550,779 股成交，较日均成交量 4,950,974 股下降了 89%。该股此前收盘价为 3.35 美元。</p>
</div><p>Get <strong>AbCellera Biologics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>AbCellera Biologics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 股价上涨 28% 及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>ABCL has been the topic of a number of recent analyst reports. Leerink Partnrs cut shares of AbCellera Biologics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, November 7th. Leerink Partners reissued a &#34;market perform&#34; rating and issued a $4.00 price target on shares of AbCellera Biologics in a research note on Friday, November 7th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of AbCellera Biologics in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of AbCellera Biologics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 8th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $7.75.</p>
<div class="lb-trans"><p>ABCL 近期成为多份分析师报告的主题。Leerink Partners 在 11 月 7 日的研究报告中将 AbCellera Biologics 的评级从 “强力买入” 下调至 “持有”。Leerink Partners 在 11 月 7 日的研究报告中重新发布了 “市场表现” 评级，并对 AbCellera Biologics 的股票设定了 4.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 AbCellera Biologics 的 “卖出（d-）” 评级。最后，Wall Street Zen 在 11 月 8 日的报告中将 AbCellera Biologics 的评级从 “持有” 下调至 “卖出”。三位投资分析师给予该股 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “持有”，平均目标价为 7.75 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on ABCL</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ABCL 的最新股票报告</strong></p>
</div><h2>AbCellera Biologics Price Performance</h2>
<div class="lb-trans"><h2>AbCellera Biologics 价格表现</h2>
</div><p>The company's 50 day simple moving average is $4.43 and its 200 day simple moving average is $4.28. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -6.25 and a beta of 0.73.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 4.43 美元，200 日简单移动平均线为 4.28 美元。该公司的市值为 10.7 亿美元，市盈率为-6.25，贝塔值为 0.73。</p>
</div><p>AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). The company had revenue of $6.51 million for the quarter, compared to analyst estimates of $6.33 million. AbCellera Biologics had a negative return on equity of 17.21% and a negative net margin of 493.42%. As a group, analysts forecast that AbCellera Biologics Inc. will post -0.59 earnings per share for the current year.</p>
<div class="lb-trans"><p>AbCellera Biologics（纳斯达克代码：ABCL - 获取免费报告）最近在 11 月 6 日公布了季度财报。该公司报告季度每股收益为（0.19 美元），低于分析师一致预期的（0.17 美元）2 美分。该公司季度收入为 651 万美元，而分析师预期为 633 万美元。AbCellera Biologics 的股本回报率为-17.21%，净利润率为-493.42%。整体来看，分析师预测 AbCellera Biologics Inc.今年每股收益将为-0.59 美元。</p>
</div><h2>Hedge Funds Weigh In On AbCellera Biologics</h2>
<div class="lb-trans"><h2>对 AbCellera Biologics 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL purchased a new position in AbCellera Biologics in the third quarter valued at approximately $3,673,000. Advisory Services Network LLC purchased a new position in shares of AbCellera Biologics in the 3rd quarter valued at $132,000. Caxton Associates LLP acquired a new stake in AbCellera Biologics during the 3rd quarter worth $1,798,000. Voleon Capital Management LP purchased a new stake in AbCellera Biologics in the third quarter valued at $56,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in AbCellera Biologics in the third quarter valued at $87,000. 61.42% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对该公司的持股。Tudor Investment Corp ET AL 在第三季度购买了价值约 367.3 万美元的 AbCellera Biologics 新头寸。Advisory Services Network LLC 在第三季度购买了价值 132,000 美元的 AbCellera Biologics 新头寸。Caxton Associates LLP 在第三季度收购了价值 179.8 万美元的 AbCellera Biologics 新股份。Voleon Capital Management LP 在第三季度购买了价值 56,000 美元的 AbCellera Biologics 新股份。最后，Sherbrooke Park Advisers LLC 在第三季度收购了价值 87,000 美元的 AbCellera Biologics 新头寸。61.42% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About AbCellera Biologics</h2>
<div class="lb-trans"><h2>关于 AbCellera Biologics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.</p>
<div class="lb-trans"><p>AbCellera Biologics Inc.构建了一个用于抗体药物发现和开发的引擎。其引擎从自然免疫反应中发现抗体，这些抗体经过预富集。该公司的临床前产品包括用于代谢和内分泌疾病的 ABCL635，以及用于特应性皮炎的 ABCL575。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than AbCellera Biologics</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Micron’s Q1 Results Say “AI Bubble Is Far From Bursting”</li>
<li>How to Start Investing in Real Estate</li>
<li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 AbCellera Biologics</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
<li>如何开始投资房地产</li>
<li>3 只便宜的股息股票可以战胜通货膨胀并支付你等待的费用</li>
<li>专家股票交易心理学技巧</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbCellera Biologics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 AbCellera Biologics 吗？</h2>
</div><p>Before you consider AbCellera Biologics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 AbCellera Biologics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 AbCellera Biologics 并不在名单上。</p>
</div><p>While AbCellera Biologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AbCellera Biologics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AbCellera Biologics（纳斯达克股票代码：ABCL）股价上涨 6.7% - 以下是原因